Choosing treatment after surgery for advanced kidney and ureter cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study helps doctors pick the best treatment for you after surgery for advanced upper tract urothelial cancer. It looks at your cancer details to guide whether more treatment, like chemotherapy, might help you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with upper tract urothelial cancer (a rare cancer of the kidney or ureter lining).
- Your cancer must be at a stage where it has grown into the muscle (stage pT2 or higher) or has spread to lymph nodes.
- You must have had surgery to remove the cancer already.
- You cannot join if your cancer is at an earlier stage (like pTa, pT1, or pTis) and has not spread to lymph nodes, or if you are missing complete medical records about your pathology and outlook.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining two drugs—toripalimab (an immunotherapy that boosts your immune system) and 9MW2821 (a targeted drug that delivers treatment directly to cancer cells)—before surgery helps shrink tumors and improves outcomes for people with upper tract urothelial cancer. The goal is to see if this combination is safe and effective before the kidney and ureter are removed.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This Phase 2 trial studies a HER2-targeted medicine (RC48-ADC) plus another drug (JS001) to help prevent cancer from coming back after surgery for upper urinary tract urothelial cancer. It may be an option if your tumor has higher HER2 levels and you have no spread to distant organs.
This trial is for people with upper tract urothelial cancer who have already had surgery and chemotherapy (cisplatin-based). It tests whether continuing with a drug called avelumab (an immunotherapy) can help prevent the cancer from coming back.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) to treat HER2-positive high-risk upper tract urothelial cancer, aiming to save the kidney instead of removing it. The drugs target cancer cells and boost the immune system to fight the cancer.
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
Hear when a new Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.